Beta Bionics, Inc. (BBNX) vs Rigel Pharmaceuticals, Inc. (RIGL)
A side-by-side comparison of Beta Bionics, Inc. and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBNX
Beta Bionics, Inc.
$18.51HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RIGL
Rigel Pharmaceuticals, Inc.
$46.72HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — BBNX vs RIGL
growth of $100 · dividends reinvested · last 2yBBNX -19.8% (-10.4%/yr)RIGL +112.5% (+45.8%/yr)RIGL compounded faster over this window
BBNX RIGL
BBNX vs RIGL: by the numbers
- •RIGL is the larger company ($864M vs $833M market cap).
- •RIGL is profitable (116.30% net margin) while BBNX runs a net loss (-61.32%).
Metrics side by side
Valuation
| Metric | BBNX | RIGL |
|---|---|---|
| P/E ratio | N/A | 2.86 |
| Forward P/E | N/A | 13.62 |
| P/S ratio | 7.00 | 3.12 |
| P/B ratio | 3.25 | 2.03 |
| EV / EBITDA | N/A | 9.40 |
| FCF yield | N/A | 9.18% |
Profitability
| Metric | BBNX | RIGL |
|---|---|---|
| Gross margin | 58.31% | 91.39% |
| Operating margin | -69.75% | 42.63% |
| Net margin | -61.32% | 116.30% |
| ROE | -28.46% | 75.67% |
| ROIC | -31.17% | 18.72% |
Growth (annualized)
| Metric | BBNX | RIGL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 13.94% |
| Total return CAGR (5Y) | N/A | 6.25% |
Frequently asked
- Is BBNX or RIGL more profitable?
- RIGL runs the higher net margin — BBNX at -61.32% versus RIGL at 116.30%.
Go deeper
Dig into the metrics
Rigel Pharmaceuticals P/E ratioBeta Bionics ROERigel Pharmaceuticals ROEBeta Bionics operating marginRigel Pharmaceuticals operating marginBeta Bionics revenue growthRigel Pharmaceuticals revenue growthBeta Bionics free cash flowRigel Pharmaceuticals free cash flow
Beta Bionics & Rigel Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.